Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections ...

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

Clostridium difficile infection, also referred to as C. difficile or C ... offering renewed hope for better patient outcomes," says a Fact.MR analyst. Leading Players Driving Innovation in ...

Mikton C. Grounds A. 2007 Vignette 1 (BPD): no sig diff in diagnosis PD. Vignette 2 (ASPD): More Caucasian than afro-Caribbean diagnosed ASPD (OR 2.6, 95% CI 1.5–4.4, p = 0.0006) or with any PD ...

Tinidazole is a structural analog of metronidazole and has been available in Europe for more than 2 decades. After activation, its toxic intermediates covalently bind to DNA, resulting in DNA ...

As it stands, PF-06425090 is still leading the field among candidate vaccines for C. diff since Sanofi ended development of its candidate in 2017, ahead of Valneva whose VLA84 has been shelved ...

This indicator covers the incidence of healthcare associated infections from Clostridium difficile (C. diff). It measures outcomes that reflect the quality of care or processes linked by evidence to ...